Q-omics provides the consensus-scored MT-CYB profile across patient tissues and cancer cell-line models. MT-CYB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MT-CYB is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MT-CYB RNA expression shows 18,598 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where MT-CYB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-CYB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-CYB survival associations across molecular data types. MT-CYB RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-CYB RNA expression–survival associations across cancer types. High MT-CYB expression shows unfavorable associations in THYM, but favorable associations in ACC, KIRP, PAAD, LUSC and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MT-CYB RNA expression.
This table summarizes MT-CYB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MT-CYB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-CYB shows lower tumor expression in KIRC, KIRP, BRCA, HNSC, LUSC and LIHC. The KIRC box plot shows higher MT-CYB RNA expression in normal versus tumor tissue (log2 FC = −1.366, t-test p < 0.001).
This table shows molecular features associated with MT-CYB in patient tissues and cancer cell lines. In patient samples, MT-CYB shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MT-CYB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
